Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Your guide to how to safely thaw and cook your Thanksgiving turkey this year, according to experts - 2Foreign military officials can become Israel's ambassadors, senior IDF commander tells 'Post'
- 3Blue Origin launches New Glenn rocket on company's first NASA-scale science mission
- 4More parents refusing this shot that prevents serious bleeding at birth
- 5Home Wellness Basics: Building Your Home Exercise center
- New materials, old physics – the science behind how your winter jacket keeps you warm
- Terminal cancer diagnosis announced by JFK's granddaughter
- 'A prank': Israel Police detain suspect for shooting rubber bullets at Ashkelon kindergarten
- How did birds survive while dinosaurs went extinct?
- Pentagon advances Golden Dome missile defense with new Space Force contracts
- Happy with Running Shoes for 2024
- Dolly Parton misses Dollywood event due to 'a few health challenges' after skipping honorary Oscars
- Fundamental Home Exercise center Hardware: Amplify Your Exercises
- 2025 Was Another Exceptionally Hot Year
